Mov Disord Vol 33, Suppl 2 Archives - Page 77 of 177 - MDS Abstracts

2018 International Congress
Novel biomarkers of autonomic regulation and sleep in Parkinson’s Disease derived from Network Physiology
O. Vaou, P. Ivanof, A. DePold-Hohler, F. Lombardi, R. Endalatpour, A. Quaicoe (Boston, MA, USA)
Objective: Utilize a novel Network Physiology approach to identify new biomarkers of Parkinson’s Disease (PD) based on the dynamics on individual physiological systems, and their…
2018 International Congress
Emulating the natural timing of dopamine receptor activation in Parkinson’s Disease
J. Reynolds, B. Hyland, J. Wickens, E. Tan (Dunedin, New Zealand)
Objective: To emulate physiological dopamine receptor activation, in order to restore temporal patterns of dopamine-like signalling and normalise function in the striatum in Parkinson's disease.…
2018 International Congress
Impact of SYN120 (a Dual 5-HT6/5-HT2A antagonist) on psychiatric symptoms in patients with Parkinson’s disease dementia: Results from a Phase 2a Study
D. Weintraub (Philadelphia, PA, USA)
Objective: To assess the psychiatric effects of SYN120 in patients with Parkinson's disease dementia (PDD). Background: SYN120 is a dual antagonist of serotonin (5-HT6 and…
2018 International Congress
Ambulosono – A Music Walking Program Improves Gait Disorders in Parkinson’s Disease
W. Xian, B. Hu, T. Wu, L. Jiang, L. Chen, Z. Pei (Guangzhou, China)
Objective: The aim of the study was to study the effect of Ambulosono - a music walking program on the walking ability of patients with…
2018 International Congress
Development of anti-amyloid drugs for Parkinson’s disease by combination screening of high-throughput in vitro assay and phenotype-based C. elegans system
K. Ikenaka, K. Araki, S. Sonoda, T. Takeuchi, Y. Nagai, Y. Goto, H. Mochizuki (Suita, Japan)
Objective: To establish a new combination screening system consisted of high-throughput in vitro assay with phenotype-based in vivo assay and to develop anti-amyloid drugs truly…
2018 International Congress
Update on The Personalized Parkinson Project: Partnering with Patients to Understand Disease Progression Through a Multi-Dimensional Approach
B. Bloem, R. Kapur, T. v/d Zande, M. Faber, W. Marks, Jr (Nijmegen, Netherlands)
Objective: Enrollment for The Personalized Parkinson Project (PPP) is underway. Co-design and mutual partnership between patients and researchers is a key characteristic of the project…
2018 International Congress
Safinamide effect in patients with Parkinson’s disease and deep brain stimulation
F. Mancini, A. Di Fonzo, G. Lazzeri, L. Borellini, V. Silano, M. Lacerenza, C. Comi (Milan, Italy)
Objective: Aim of this retrospective study is to evaluate safety and efficacy of safinamide in the treatment of motor complications in patients with Parkinson’s Disease…
2018 International Congress
After Deep Brain Stimulation Surgery for Parkinson’s Disease risk Factors for Postoperative Delirium
F. Rakhimov, G. Rakhimbaeva (Tashkent, Uzbekistan)
Objective: The aim of this study was to investigate the incidence of and risk factors for postoperative delirium (POD) after deep brain stimulation (DBS) surgery…
2018 International Congress
On Converting Patients From Oral Dopamine Agonists to the Carbidopa/Levodopa Enteral Suspension Method – Real World Conversion Ratios
S. Nakano, L. Bahroo, F. Pagan, F. Amjad, S. Lo, I. Gambhir (Washington, D.C., DC, USA)
Objective: To review guidelines for initiating Carbidopa/Levodopa Enteral Suspension method of delivery in the treatment of Parkinson’s Disease (PD) and to compare guidelines with real…
2018 International Congress
Clinical trial protocol: Restitution of oral transport, penetration and aspiration with nigral stimulation in Parkinson’s disease?
A. Schoellmann, L. Stoll, B. Hobl, C. Meisner, A. Gharabaghi, D. (Tuebingen, Germany)
Objective: In this randomized controlled clinical trial, we aim to characterize the differential effect of subthalamic nucleus (STN) or subthalamic nucleus and substantia nigra pars…